ReviewCancers2019
Management of Small Bowel Neuroendocrine Tumors.
Review in Cancers, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 37 citations in OpenAlex.
- The Use of Adjunct Therapies with Surgery for Gastroenteropancreatic Neuroendocrine Tumors: Indications, Timing, and Outcomes.Biomedicines · 2026Review
- Small bowel obstruction from metastatic small intestinal neuroendocrine tumor managed solely with somatostatin analog.JCEM case reports · 2026Article
- Article
- Calcitonin-producing Duodenal Neuroendocrine Tumor: A Case Report and Literature Review.Endocrine, metabolic & immune disorders drug targets · 2025Review
- Current Status of Immunotherapy in Management of Small Bowel Neuroendocrine Tumors.Current oncology reports · 2024Review
- Morbidity and Outcomes of Primary Tumor Management in Patients with Widely Metastatic Well-Differentiated Small Bowel Neuroendocrine Tumors.Annals of surgical oncology · 2024Article
- ASO Author Reflections: Morbidity and Outcomes of Primary Tumor Management in Patients with Widely Metastatic Well-Differentiated Small Bowel Neuroendocrine Tumors.Annals of surgical oncology · 2024Article
- Incidental intraoperative finding of jejunal neuroendocrine tumors during elective ventral hernia repair.Journal of surgical case reports · 2023Article
- Emerging Immunotherapeutic and Diagnostic Modalities in Carcinoid Tumors.Molecules (Basel, Switzerland) · 2023Review
- Small bowel neuroendocrine tumors: An analysis of clinical presentation, diagnostic workup and surgical approach-A single center retrospective study.Frontiers in surgery · 2023Article
- Circulating hsa-miR-5096 predictsFrontiers in oncology · 2023Article
- Diagnosis and management of small bowel neuroendocrine tumors: A state-of-the-art.World journal of methodology · 2022Review
- Review
- Biomarkers in Small Intestine NETs and Carcinoid Heart Disease: A Comprehensive Review.Biology · 2021Review
- Antiproliferative Systemic Therapies for Metastatic Small Bowel Neuroendocrine Tumours.Current treatment options in oncology · 2021Review
- Article
- Molecular Pathology of Well-Differentiated Gastro-entero-pancreatic Neuroendocrine Tumors.Endocrine pathology · 2021Review
- Laboratory, Clinical, and Survival Outcomes Associated With Peptide Receptor Radionuclide Therapy in Patients With Gastroenteropancreatic Neuroendocrine Tumors.JAMA network open · 2021Article
- Frequency, prognosis and treatment modalities of newly diagnosed small bowel cancer with liver metastases.BMC gastroenterology · 2020Article
- Survival in Patients with Neuroendocrine Tumours of the Small Intestine: Nomogram Validation and Predictors of Survival.Journal of clinical medicine · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Several important landmark trials have reshaped the landscape of non-surgical management of small bowel neuroendocrine tumors over the last few years, with the confirmation of the antitumor effect of somatostatin analogue therapy in PROMID and CLARINET trials as well as the advent of therapies with significant potential such as mammalian target of rapamycin inhibitor (mTor) everolimus (RADIANT trials) and peptide receptor radionuclide therapy (PRRT) with 177-Lutetium (NETTER-1 trial). This narrative summarizes the recommended management strategies of small bowel neuroendocrine tumors. We review the main evidence behind each recommendation as well as compare and contrast four major guidelines, namely the 2016 Canadian Consensus guidelines, the 2017 North American Neuroendocrine Tumor Society guidelines, the 2018 National Comprehensive Cancer Network guidelines, and the 2016 European Neuroendocrine Tumor Society guidelines. Different clinical situations will be addressed, from loco-regional therapy to metastatic unresectable disease. Carcinoid syndrome, which is mostly managed by somatostatin analogue therapy and the serotonin antagonist telotristat etiprate for refractory diarrhea, as well as neuroendocrine carcinoma will be reviewed. However, several questions remain unanswered, such as the optimal management of neuroendocrine carcinomas or the effect of combining and sequencing of the aforementioned modalities where more randomized controlled trials are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.